INTRODUCTION
Classically, inhibin was defined by its endocrine activity in suppressing follicle stimulating hor-o~e (FSH) secretion by the pituitary and by pItuItary cells in culture. \ It was first identified as a product of the ovary and testis (see Fig. I ).
. I?hibin is a heterodimeric glycoprotein consl.stlng of an ex subunit covalently linked by dlsulphide bridges either to a fJA subunit (inhibin A) or to a Po subunit (inhibin B).\ Three differently processed size isoforms of the ex s~bunit (pro-exN-exC, exN-exC, «C) are combined with either of two fJ subunits (pro-fJA-fJA and PA) to give potentially at least six different forms of bioactive inhibin A, and a similar number of isoforms of inhibin B (pro-fJB-PB and fJB). 2 In addition, human body fluids contain forms of the ex subunit not associated with a fJ sUbunit, and lacking inhibin bioactivity. The major forms of free ex subunit are pro-exC and Pro-exN-exc. 2 These various molecular structures are shown in Fig. 2 .
Early bioassays developed using cultured pituitary cells had numerous disadvantages. !he most important of these was the presence In human fluids of molecules which both inhibit and stimulate FSH production. These latter proteins, termed activins, are dimers of the inhibin fJ subunit. The net effect on cultured pituitary cells was thus a complex global average of positive and negative effects rather than a true measure of inhibin alone. It was recognized that i~munoassays would be required to achieve high sensitivity and specificity combined with practical convenience. ' At the time of a 1993 review of the clinical utility of inhibin measurement.' a single immunoassay for inhibin was available. Known as the 'Monash assay', this was a classical radioimmunoassay using a polyclonal antiserum raised to This article was prepared at the invitation of the Clinical Luhoratory Investigations Standing Committee of the Assoeiution of Clinical Biochemists. Correspondence: Prof. N P Groome. E-mail: npgroomera.brookcs.ac. uk purified inhibin, with iodinated 31 kDa inhibin as the tracer.' However, the antibodies used in this assay were directed towards epitopes on the ex subunit and could not distinguish dimeric inhibin A and B from free ex subunits.' The assay was said to measure 'immunoreactive' inhibin. This review identified a need for more specific immunoassays able to measure inhibin A and B in the presence of free ex subunit. Only one definite clinical application of the Monash assay was described in this review, namely the diagnosis and monitoring of women with ovarian cancer. The inhibin A and B assays developed in the authors' laboratory have now helped to clarify the biological role of these hormones and enabled a reassessment of the potential clinical applications of inhibin assay. In the following review, we summarize the main findings regarding inhibin structure and physiology, and the emerging clinical potential of inhibin assays. The details of the inhibin A and Band inhibin pro-exC enzyme-linked immunosorbent assays (ELISAs) are described in detail elsewhere"? and will not be covered here. At the time of the 1996 review of the clinical applications of inhibin assays by Wallace and Healy,8 the value of inhibin A as a Down's syndrome screening marker had just been discovered. In the last few years many researchers have begun to use the inhibin A and B ELISAs, and this is revealing many more potential clinical applications.
INHIBIN STRUCTURE
The various size isoforms of inhibin A and inhibin B, and the two main forms of free exsubunit (pro-aC and pro-exN-exC) are shown in Fig. 2 . The molecular weights of some of the forms are reported as described either by Mason et al.' or Robertson et al. to Other groups report slightly different weights according to the standards used for sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE). The presence of several glycosylation sites throughout the subunits complicates interlaboratory comparison of sizes. Previous studies of various size forms by Sugino and coworkers" had suggested that many of the high-molecularweight forms had bioactivity in the pituitary bioassay identical to that of the fully processed dimer (33-36 kDa). However, it was possible that the larger forms were cleaved to the small form during the bioassay. More recently, Mason et al. 9 constructed non-cleavable forms of inhibin A by altering the dibasic processing sites. Using these inhibins, it was shown that 55 kDa and 65 kDa inhibin A containing partially processed (J. subunit were fully bioactive even though they could not be processed in the normal way.? Robertson et al. have shown in a series of studies that some of the partially processed inhibin forms are present in ovarian follicular fluid and in human serum. l ll,12,1) It appeared that the inhibin A and B were differentially processed, with serum from both men and women containing 33~36 kDa and 66 kDa forms of inhibin B, with little 55 kDa form. By contrast, in women the 55 kDa form of inhibin A was also present." There is currently no information on any differential functions for these various inhibin size isoforrns, and currently there arc no methods to measure them separately by immunoassay. Thus, it is unknown whether inhibin processing is altered in any disease states.
TISSUE LOCALIZATION OF INHIBIN AND ITS RECEPTORS

Tissue localization
Whereas the synthesis and secretion of dimeric inhibin A and B arc confined to the reproductive system (ovary, testis, placenta and foetoplacental unit), a wider range of tissues make either only activins (no synthesis of e-subunit) AIIII Clin Hlorhem 2000: 37 or only free inhibin (J.-subunit (no p-subunit). Tissues known to make the (J.-subunit only include brain!" and adrenal gland." No clear function has been identified for the free (J.subunit at these extragonadal locations other than as a means to reduce the amount of activin synthesis. Knockout mice unable to make the inhibin «-subunit have high activin levels and consistently develop ovarian tumours. If the ovaries are removed these mice develop adrenal tumours. Thus, inhibin (J. functions as a tumour suppressor." As described in a later section, various epithelial ovarian cancers or their supporting stromal cells secrete immunoreactive inhibin into the circulation."
Receptors
For many years no specific inhibin receptor could be identified. It was therefore thought that inhibin functioned by using its p-subunit to compete with activin receptors. 1M Recently, however, an inhibin receptor has been identified in gonadal tumours from inhibin e-subunit knockout mice." There is also evidence for an inhibin receptor on ovine pituitary cells." Therefore, it seems that inhibin may directly exert its effects by interaction with the activin receptor and its own receptor. Details of the tissue distribution of the inhibin receptor have yet to emerge. The consequence of this is the possibility of higher interassay variability, due to the failure of real samples to respond in the same way as the standards to changes in plate batch or day-to-day variation in incubation temperatures, wash times, etc. We believe that serum-based standards and/or calibrators would be optimal; there is a need for a panel of real patient serum calibrators to serve as international reference samples for various clinical applications. This could include a male serum pool for use in association with inhibin B assays in men, a pool of female serum taken on days 3 5 of the menstrual cycle for use as a reference material when inhibin B is used as a marker for ovarian reserve, and a second-trimester pregnancy pool for use with the inhibin A assay in prenatal screening. There is a need for new immunoassays capable of specifically measuring the high-molecular-weight forms of inhibin A and B in the circulation. New monoclonal antibodies for this purpose are currently being evaluated in our laboratory.
Binding proteins
PHYSIOLOGICAL BACKGROUND
Female
In the human menstrual cycle, serum inhibin A and inhibin B concentrations have different temporal profiles." Inhibin A is maximal in late follicular phase and luteal phase, whereas apart from a peak at ovulation, inhibin B is maximal in early follicular phase (see Fig. 3 ). 5 It is believed that while inhibin A is made largely by the dominant follicle, inhibin B is made by small, recruitable antral follicles. Inhibins were originally thought to exert an endocrine action in suppressing FSH production by the pituitary. More recently, local paracrine actions have been suggested.P'" Although many putative paracrine actions remain undefined, the ability of inhibin A in ovarian follicles to stimulate thecal cell androgen synthesis has been clearly established." The major peak of serum inhibin A is in luteal phase." Attempts to show an endocrine role for inhibin at this stage of the cycle by immunoneutralization were unsuccessful,26 and it is generally thought that negative control of FSH shifts from oestradiol in the luteal phase to inhibin B in the mid-follicular phase." However, in rhesus monkeys, intravenous administration of physiological concentrations of recombinant inhibin A in mid-luteal phase did reduce serum FSH levels." At the present time therefore, the function of inhibin A in luteal phase is uncertain, and may vary between species.
By contrast to inhibin A, there is a consensus emerging for a key role of inhibin B in the regulation of circulating FSH during early and mid-follicular phase. 29,30 Primate studies have revealed that the rise in FSH at the start of the cycle is the major stimulus for inhibin B secretion. 27.31 Reproductive ageing is associated with a rise in early follicular phase FSH and a fall in inhibin B.32 Unavailability of purified inhibin B has hindered direct attempts to test its endocrine activity on primates.
A continuing unresolved issue is the function of large concentrations of the free inhibin a subunits pro-rxC and pro-rxN-rxC found in excess over bioactive inhibin forms in most biological fluids. An early suggestion by Schneyer et a/. 33 that such forms might modulate FSH binding to its receptor has not been independently confirmed. A recent report by Silva et a/. 34 suggested that intrafollicular pro-rxC might modulate oocyte development, although the effect found was not dramatic. Immunization of sheep with peptides from the eN region of the e-subunit impairs fertility by an unknown mechanism.Pr" These findings suggest that much remains to be understood about the functions of inhibin regions other than those with FSH-suppressing function. During early pregnancy, serum inhibin A concentrations start to rise,37,38 the foetoplacental unit being the major source." Very high serum inhibin A concentrations are found at the end of pregnancy.v-" Inhibin A and B are also found in extra-embryonic coelomic and amniotic fluids. 42.43 No clear function has so far been identified for bioactive inhibin forms at these various locations during pregnancy, although the placenta is a source of a wide range of molecules with potential paracrine actions."
Male
Men do not appear to secrete inhibin A into the circulation. By contrast, inhibin B is present, and correlates inversely with FSH. 45 49 It is now widely believed that inhibin B is the physiologically relevant regulator of FSH levels in men."
Circulating inhibin B levels reflect both Sertoli cell number" and the maturational state achieved by the sperm." A review of the endocrine role of inhibin A and B in men and women was recently published.'? 52 ,53 had suggested that immunoreactive inhibin was elevated in the maternal serum of women carrying pregnancies affected by trisomy 21. However, this proved to correlate closely with human chorionic gonadotrophin (hCG), thereby not adding value as an additional marker for prenatal screening. By contrast, when the ELISA for dimeric inhibin A became available, this seemed to be much morẽ sefuJ. Initial studies suggested some usefulness In the first trimester, 54 but these have not yielded as consistent results as has screening in the second trimester,55,56 The major findings in relation to inhibin A and second trimester screening are as follows, I. Aitken et al. 57 found that when AFP (IXfetoprotein), the beta subunit of hCG and maternal age alone were used as predictors in the second trimester the rate of detection of Down's syndrome was 53%, with a false positive rate of 5%. Inclusion of inhibin A improved the detection rate to 75%, with the same false positive rate. These authors found little value for inhibin A in the detection of cases of trisomy 18. In their opinion, a major advantage of the use of inhibin A as a screening marker for Down's syndrome was the very small change in average inhibin A concentrations between 15 and 18 weeks' gestation, allowing some error in assessing gestation time. 2. Wald et al. 58 Although there is general agreement on the value of inhibin A as a marker for Down's screening, it is not clear whether inhibin A has anything to add to screening for other trisomies. Aitken et al. 57 found no value in trisomy 18, but Wenstrom et al. found that a two-marker test with just inhibin A and AFP detected 12/13 cases of trisomy 18 and 9/17 of Turner's syndrome.s? Several centres have now introduced inhibin A as a Down's screening marker in the second trimester. In the light of developments in ultrasound screening, the long-term future of biochemical screening for Down's syndrome is uncertain, but inhibin A appears to enhance the performance of the existing screening tests for as long as they are used. Very recently, Wald et al. 7o reported that using a combination of first-and second-trimester markers (including inhibin A) for screening achieved an 85% detection rate with a false positive rate of 0·9%. However, this method is unlikely to gain wide acceptance due to both clinical and ethical problems."
Prenatal screening for pre-eclampsia Pre-eclampsia is an important complication which can arise during pregnancy. It affects 5-10% of pregnancies to some extent. There is general agreement that early screening for higher risk of pre-eclampsia is needed. A study by Muttukrishna et al. n reported that in 20 women with established pre-eclampsia the mean concentrations of maternal inhibin A (3'05 ng/ml.) were much higher than in controls matched for duration of gestation, parity and maternal age (0,36 ng/ml.), For this small sample set there was no overlap between cases and controls. The major question unresolved by this study was whether the elevation in inhibin A preceded the onset of symptoms. One recent study by Cuckle et al. 73 examined women at 13-18 weeks' gestation, the same time as when serum samples are usually taken for Down's syndrome screening. They found that the median inhibin A concentration for those who later (on average, 22 weeks later) developed pre-eclampsia was 2·01 multiples of the gestation-specific median in the controls. Similar evidence for the predictive value of inhibin A at 15-19 weeks' gestation was reported by Aquilina et al." If these results can be confirmed there are several implications. A small proportion of the women with elevated inhibin A may actually have Down's syndrome pregnancies. Clearly, this would have to be excluded before the women could be assumed to be at an increased risk of pre-eclampsia. Secondly, susceptibility to pre-eclampsia may account for many of the false positives currently observed when inhibin A is used as a Down's syndrome screening marker.
In the study by Cuckle et al," the concentrations of other Down's syndrome markers were similar in pre-eclampsia and controls. If further screening markers for pre-eclampsia could be developed one could imagine analysis software which first identified the women at high risk of pre-eclampsia and then separately tested the risk of Down's syndrome. Inhibin A might then become an improved marker for Down's syndrome.
Investigation of reproductive ageing and in vitro fertilization
As more women choose to have their children later in life, the monitoring of the process of reproductive ageing is of growing importance. It has been known for some time that as women age their serum FSH levels in early follicular phase rise. This has recently been suggested to be caused by a decline in the number of small follicles secreting inhibin 8. 32 8urger et al. 75 identified a fall in circulating follicular phase inhibin 8, in the absence of changes in oestradiol and inhibin A, as the most significant endocrine event in the peri-menopause transition. Similar observations were made by Welt et al. 76 Danforth et al. report a fall in circulating inhibin A during the luteal phase of women undergoing the menopause transition." Seifer et al. examined whether inhibin 8 serum concentrations on day 3 of normal menstrual cycles could be used as a predictor of ovarian reserve and the outcome of in vitro fertilization.P They defined a cut-off serum concentration of inhibin 8 and were able to divide the women into two groups. Those with concentrations above the cut-off had more oocytes retrieved per patient, a higher percentage of clinical pregnancies and a lower cancellation rate per initiated cycle (i.e. cancellations due to inadequate response) than those in the low inhibin 8 group. On this basis, the authors concluded that inhibin B had some potential in identifying women with a low chance of a successful outcome for assisted reproduction."
The same authors later investigated whether inhibin B might be the physiological basis for the clomiphene citrate challenge test, commonly used to assess ovarian reserve." Clomiphene citrate (Clomid, Serophene) blocks the effects of oestradiol on the pituitary and induces it to increase FSH production. Women with decreased ovarian reserve were known to produce higher levels of FSH after treatment with clomiphene citrate, although the mechanism was unknown. The new finding" was that on day 3 and day 10 of the test women with diminished ovarian reserve had lower serum inhibin 8 concentrations and that on both days this was negatively correlated with serum FSH. The authors proposed that in the older women the lower inhibin B output by the smaller number of small follicles was the central physiological mechanism of the clomiphene citrate challenge test." At present it is not clear whether inhibin 8 adds significantly to the existing tests for ovarian reserve." It may add value to the measurement of FSH alone, because serum inhibin 8 is more constant from cycle to cycle than FSH. A very recent paper by Seifer et al. K1 claims that declining ovarian reserve may be revealed by a decrease in day 3 serum inhibin 8 before a rise in day 3 FSH is detected.
Other potential applications of inhibin assays in relation to in vitro fertilization (IVF) have been proposed. Eldar-Geva et al. K2 found that serum inhibin 8 concentrations measured during the early stages (days 4-6) after administration of fixed-dose recombinant human FSH treatment provided an early predictor of the number of recruited follicles. Lindheim et al. have shown that the measurement of inhibin A may be used to identify the women undergoing natural-cycle in vitro fertilization-embryo transfer (IVF-ET) who should be prepared for e~~retrieval.V Lockwood et al. 84 found initially nsmg levels and then a rapid decline of maternal serum inhibin A in pregnancies with embryonic failure, indicating a possible clinical a~plication in the diagnosis of failed pregnancies, There are possible advantages here over existing markers: progesterone and hCG con-ntr~tions might both be expected to remain high in the continued presence of a functioning o~~s luteum and placental sac, whereas IUhlbm A is made by the foeto-placental unit.~~t her studies are required to confirm the Imbal observation and demonstrate clinical ut~lity. Since assisted pregnancies have a higher f~dure rate than spontaneous pregnancies and Since a successful outcome is so keenly awaited, this potential application of inhibin assay is Worth exploring.
Finally, Lockwood et al. 85 have investigated the serum concentrations of inhibin B in women with polycystic ovarian disease. It was found that serum inhibin B concentration was much h!gher in patients with pca (polycystic ovarian disease), as might be expected from the larger nUmber of small follicles likely to be present iñ he ovary. Furthermore, whereas the serum mhibin B concentrations in normal women had regular periodicity, this periodicity was absent m patients with pca. When participating in IVF programmes, women with pca are at significantly greater risk of developing ovarian hyperstimulation syndrome. It would be very valuable if women with pca at higher risk could e identified by their pre-treatment serum inhibin B concentrations as a reflection of the nUmber of recruitable follicles. If a relationship between inhibin B and risk of ovarian hyperstimulation syndrome can be established for WOmen with pca, it may be possible to extend this to determine whether hyperstimulation in ordinary women is associated with high inhibin B on day 3 of the cycle. It is too soon to say which, if any, of these potential applications will become widely used for routine purposes. However, inhibin assay clearly has a role in research studies of both reproductive ageing and in vitro fertilization.
Clinical role of inhibin measurement 425
Investigations of male reproductive function
Until very recently, the physiological role of inhibin in men was unclear. However, the availability of the new inhibin A and B immunoassays" has transformed this situation into an active field of research." Men do not appear to possess circulating inhibin A. By contrast, inhibin B is present in serum and its concentration correlates inversely with that of FSH, in a fashion consistent with its predicted role as a negative endocrine regulator of FSH.45 Inhibin B is a Sertoli cell product and in the adult appears to be a good indicator of active spermatogenesis. Several studies describe a good correlation between inhibin B and both testicular volume and sperm density.47--49 A recent study concluded that the combined measurement of inhibin Band FSH provided a better indicator of whether the individual was likely to have adequate or impaired spermatogenesis than did either marker alone." This was confirmed in an independent study by von Eckardstein et al.,86 who found that measurement of inhibin Band FSH had high diagnostic sensitivity (88%) and specificity (83%) for the presence of elongated spermatids in biopsies. The same combination showed a sensitivity of 75% and a specificity of 73% when identifying patients in whom sperm could possibly be retrieved by testicular sperm extraction, but was felt to fall below an acceptable threshold as a reliable predictor in individual cases." Two studies report that serum inhibin B alone cannot reliably distinguish between individuals with normal sperm and those with various types of spermatogenic arrest, in whom inhibin B may be normal. 87 • 88 Serum inhibin B has proved a useful marker for population studies of male fertility, providing an additional marker to FSH and sperm density." Serum inhibin B was used in the study by Nachtigall et al. 90 to identify men with hypogonadotrophic hypogonadism who were likely to have a better clinical outcome after treatment with gonadotrophin releasing hormone (GnRH), these being the men with higher basal levels before treatment. The basal serum inhibin B concentration was taken to reflect the testicular content of Sertoli cells. However, there was no distinct separation between the groups, and clinical utility would require careful establishment of cut-off levels.
Wallace et al. 91 reported that inhibin B can be used to monitor chemotherapy-induced testicular damage in men being treated for haematological malignancies. After treatment, sperm density and serum inhibin B levelsfell and serum FSH rose. In contrast to these results with the inhibin B assay, the immunoreactive inhibin detected by the Monash assay actually increased during the treatment, emphasising how the more specific assays are providing different and generally more useful results from the same samples.
In conclusion, inhibin B assay studies in men are providing valuable insights into physiology and provide a useful research tool, but it is not clear whether routine clinical applications will emerge. The demonstration of a significant diurnal variation of serum inhibin B in men means that precise comparative studies may require the time of day at which serum is collected to be standardized.f
Ovarian cancer Granulosa cell tumours
The overall 5-year survival rate from ovarian cancer is still only around 30%, and this has not improved for almost 30 years. Granulosa cell tumours of the ovary represents about 5% of total ovarian cancers. They are often slow growing, late recurrences after treatment are common, and there is a need for long-term monitoring of such patients. Immunoreactive inhibin, detectable by the Monash radioimmunoassay, has been shown to be a useful circulating marker for granulosa cell tumours." Levels of immunoreactive inhibin were elevated prior to surgery, fell after surgery and remained at baseline unless recurrence occurred. It is easier to interpret results in women who have had bilateral ovariectomy, or who are post-menopausal. Interpretation of results in women with residual secretion of ovarian inhibin is complicated by the variations of serum inhibin concentrations through the normal cycle. In principle, results could be interpreted better if collection of samples was always in the first few days of menstrual bleeding, when secretion of immunoreactive inhibin is low.
However, serum contains forms of the inhibin ex subunit of non-ovarian origin and thus there will always be a significant residue of immunoreactive inhibin which is unrelated to the presence of tumour. This has led to speculation that dimeric inhibin A and/or B might be better tumour markers because in ovariectomized or post-menopausal women all dimeric inhibin would come from tumour. Several groups investigated the molecular form of the inhibin secreted by granulosa cell tumours and found Ann cu« Biochem 20llO: 37 that although many tumours made inhibin A,94 all produced inhibin B.9S Since granulosa cell tumours are relatively rare, serial monitoring is best done nationally or regionally by a tumour marker laboratory able to maintain the necessary assay quality control system. Although on the basis of published information one can infer the practical applicability of inhibin B as a granulosa cell tumour marker, this has not been conclusively demonstrated.
Epithelial cell tumours
Healy et al. 17 showed immunoreactive inhibin to be a useful marker for patients with mucinous carcinomas of the ovary. In their study, 18 of22 women with mucinous carcinomas had elevated serum concentrations before surgery and the concentrations fell to low levels after surgery. In contrast to granulosa cell tumours, epithelial ovarian tumours make little dimeric inhibin and best results seem to be achieved by the less specific assays which recognize all molecular forms of inhibin, including bioactive dimeric forms and free ex subunits. Lambert-Messeriian et al. 96 found that immunoassay for inhibin pro-exC combined with CAl25 detected more ovarian cancers (87%) in a screening application than did CAl25 alone (78%). Robertson et al. 97 obtained similar results with a new immunoflurometric assay which detected multiple forms of the inhibin ex subunit. Approximately 90% of tumours were detected in the study by Robertson et al. The main reason for enhanced detection is that CA 125 is less effective in the detection of mucinous tumours, where inhibin is particularly useful. A recent study by Frias et al. 98 showed that by use of a specific inhibin A ELISA, valuable prognostic information could be gained from postmenopausal women with epithelial ovarian carcinomas.
Some authors have expressed doubts about the case for mass screening for ovarian cancer, pointing out that in a population with an incidence of 40 per 100000, if no cancers were missed and all detected cancers were treated successfully, the absolute reduction in morbidity would only be about I in every 2500 screened women per year." To be offset even against this limited benefit is the fact that, depending on the false positive rate in the screening, many women will be exposed to the risks of unnecessary exploratory surgery. It is possible that the major application of inhibin will be post-operative follow-up of patients and the detection of recurrence.
PUbertỹ espite the large number of publications which diSCUSS inhibin A and B concentrations in the adult male and female pituitary-gonadal axis, there are very few that concentrate on these proteins during puberty. Results from a recent study by Crofton et al. loo show for the first time that the expected negative relationship between serum inhibin Band FSH levels is only es~ablished in boys at the onset of puberty. PrIOr to this, a positive relationship between the two is evident. Two other studies have found that the serum concentration of inhibin B is elev~ted during infancy. The inhibin B concentrations are strikingly high at approximately 3 months and remain so until around 15 months old, whereas the levels of FSH, LH and testosterone decrease between 6 and 9 months. As inhibin B is a product of Sertoli cells, its pr?longed elevation in infant boys suggests that this period may be an important developmental stage in Sertoli cell proliferation and maturation. 101 -103 Therefore, measurement of serum inhibin B concentrations in infant males may serve to predict abnormal Sertoli cell development in early life. However, such intervention poses ethical issues. Evidence suggests that Impaired Sertoli cell numbers will adversely affect adult fertility. 90 . In young girls, ovarian follicles produce both !nhibin A and B, the concentrations of which Increase as puberty progresses.P" Therefore, the measurement of both these could be used to determine gonadal maturity in girls. At the present time, 'normal' ranges for serum inhibin A and inhibin B at various ages are being stablished, which may enable an application in Investigating development of the reproductive system.
Miscellaneous
A limited number of studies have investigated serum inhibin concentrations in women with ectopic pregnancies; Seifer et al. found concentrations to be lower than in intrauterine pregnancies. 104 0'Antona et al. investigated the use of serum inhibin A measurements as a surveillance marker after removal of the foetus in tubal pregnancies to exclude persistent ectopic pregnancy. !Os However, interpretation of the results from this study was complicated by the Increase in inhibin A concentrations resulting from the return of normal ovarian function. Inhibin, intact hCG and the fl-subunit of hCG may be useful in the diagnosis of hydatidiform Clinical role of inhibin measurement 427 mole.l'" The postulated advantage over hCG measurement was the shorter half-life of serum inhibin, but as information about this is limited, we do not yet know whether these applications will be of clinical use. Another application which may be of clinical significance is the measurement of inhibin to detect women with abnormal luteal function. At present, the recommended marker of lutealphase dysfunction is a mid-luteal serum progesterone level below 10ng/ml., 107 Yamoto et al. w 7 found the corresponding inhibin A concentration to be significantly depressed, while serum inhibin B was normal. Illingworth et al. 38 found that concentrations of both serum inhibin A and pro-acC, but not of inhibin B, significantly increased during mid-luteal phase following hCG administration. These findings, taken together with those of Yamoto et al., indicate the corpus luteum to be a source of inhibin A but not inhibin B. Since assays for progesterone are cheap and automated, some advantage of inhibin A assay (not apparent at present) would need to be demonstrated to justify routine use.
CONCLUSION
The large amount of research made possible by the new inhibin A and inhibin B ELISAs is gradually leading to clinical appiications. At present, however, only prenatal screening for Down's syndrome has become widely accepted clinically. New information about inhibin physiology is finding its way into undergraduate medical training courses and texts and can only accelerate the rate at which the assays are applied. Oxford Brookes University maintains a very detailed web site which contains a complete list of publications employing inhibin immunoassays and other advice for users of the assays. This is to be found at http://www.brookes.ac.uk/inhibin and is updated every 2 weeks.
